EGFLAM inhibitors are a class of chemical compounds that target and modulate the activity of EGFLAM, a specific protein of interest in various biological processes. EGFLAM, which stands for EGF-like, fibronectin type III and laminin G-like domain-containing protein, is a protein found in the extracellular matrix of tissues and is involved in various cellular functions, including cell adhesion, migration, and tissue development. These inhibitors are designed to interact with EGFLAM and influence its function, making them valuable tools for researchers in the fields of cell biology and molecular biology.
EGFLAM inhibitors typically work by binding to EGFLAM and altering its conformation or blocking its interaction with other proteins or molecules. By doing so, they can modulate cellular processes that depend on EGFLAM, such as cell adhesion to the extracellular matrix or signaling pathways that involve this protein. Researchers use EGFLAM inhibitors in laboratory settings to better understand the role of EGFLAM in cellular and tissue physiology. These inhibitors can also be instrumental in elucidating the molecular mechanisms underlying diseases or conditions in which EGFLAM is implicated. Their precise mechanisms of action and downstream effects can vary depending on the specific inhibitor and its chemical properties, making them versatile tools for scientific investigations aimed at unraveling the complexities of cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a tyrosine kinase inhibitor that competes with ATP for binding to the EGFR kinase domain. It inhibits EGFR autophosphorylation and downstream signaling, suppressing tumor cell growth. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is also a tyrosine kinase inhibitor that selectively targets EGFR. It binds to the ATP-binding site of EGFR, blocking phosphorylation and downstream signaling, inhibiting cancer cell proliferation. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Afatinib irreversibly inhibits EGFR and other HER family receptors by forming covalent bonds. This hinders receptor activation and downstream signaling, slowing cancer cell growth. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib is a third-generation EGFR inhibitor that targets mutated EGFR variants. It blocks EGFR kinase activity, impeding the growth of EGFR-mutated cancer cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual EGFR/HER2 inhibitor that interferes with both receptors' kinase activities. It halts signaling cascades in cancer cells, reducing their proliferation. | ||||||